{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"","title":"This CDMO Has an Advantage No One Else Can Replicate - Quotient Sciences","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1776779824882-5d104b2b-af07-4c3a-a52d-6d486bc4fdb1.jpeg?height=200","description":"

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.


The CDMO model is evolving fast, but what actually separates the leaders from the rest in today’s market?


This week on Making It In Manufacturing, Harry Sloan sat down with Thierry Van Nieuwenhove, CEO of Quotient Sciences, with 25+ years of experience spanning business development, engineering, global manufacturing leadership, and executive roles.


In this episode, Thierry covers:


• The evolution of the CDMO landscape over 25 years, from API-focused events to a global, multi-disciplinary pharma ecosystem

• How Quotient Sciences built a unique translational pharmaceutics platform to combine clinical studies with drug manufacturing, accelerating development timelines by up to 12 months

• A career journey from chemical engineering into global business development and leadership, including building manufacturing capabilities in India and working across Europe and the US

• Why speed, efficiency, and proof of concept are critical in today’s funding-constrained biotech environment

• The growing impact of AI, global innovation shifts including China, and how CDMOs must adapt to remain competitive and support emerging biotech pipelines


If you are looking to understand where the CDMO space is heading, and what it takes to lead in a rapidly evolving pharmaceutical market, this episode offers a clear and practical perspective. Be sure to watch the full conversation.


Follow ARTO


LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences


Thierry Van Nieuwenhove

CEO at Quotient Sciences

LinkedIn: https://www.linkedin.com/in/thierryvan/


Harry Sloan

BD CDMO Lead

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/


Timestamps:

00:00 Introduction to Making It In Manufacturing at DCAT

00:20 Meet Thierry Van Nieuwenhove, CEO of Quotient Sciences

01:40 Overview of Quotient Sciences and translational pharmaceutics

03:10 Competitive advantage in the CDMO market

04:23 Career journey from engineering to CEO

07:00 Leadership development across global roles

08:18 Operating across international markets and cultures

09:17 Translating early-stage assets into clinical success

12:00 Industry challenges including funding constraints

14:25 AI, partnerships, and innovation in formulation

16:01 Data science and accelerating development timelines

17:32 Global trends including China’s role in innovation

19:56 Strategic adaptation to industry shifts

21:34 Demand for integrated CDMO models

22:55 Customer expectations: speed, excellence, and innovation

25:28 The importance of trust and long-term partnerships


#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #Biotech #DrugDevelopment #LifeSciences

","author_name":"ARTO Talent"}